Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Pila Pharma AB is a biotechnology company dedicated to advancing pharmaceuticals that address significant unmet medical needs. The primary focus is on developing innovative treatments, with a special emphasis on metabolic disorders, such as type 2 diabetes. Pila Pharma AB leverages its proprietary technology to create novel drug candidates aimed at enhancing patient outcomes and improving quality of life. Based in Sweden, the company is strategically positioned in a burgeoning biotech landscape, contributing to cutting-edge research and development in the pharmaceutical sector. The company's approach emphasizes rigorous clinical trials and collaborations with academic institutions to ensure the efficacy and safety of its therapeutic offerings. Pila Pharma's presence in the financial market is noteworthy, as it represents an intersection of science and commerce, providing investors with exposure to the high-risk, high-reward biotechnology sector. The company's efforts to innovate within the diabetes treatment space underscore its commitment to addressing global health challenges and position it as a pivotal player in the ongoing pursuit of medical advancements.
kr 0.11
+kr 0.00 (+4.21%)
EOD Jun 25, 2026 · Twelve Data
The business is unprofitable at the operating level (-713.00% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 45.4% YoY with margins expanding 333.5pp.
Negative free cash flow of -kr 7M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 1M
▲ +45.4% YoY
Net Income (TTM)
-kr 17M
▼ -51.3% YoY
Op. Margin
-713.00%
▲ +333.5pp YoY
ROIC
-63.76%
▲ +43.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 7M
▲ +15.2% YoY
Op. Cash Flow (TTM)
-kr 7M
▲ +15.2% YoY
Net Debt
-kr 16M
Net Cash Position
Cash & Equiv.
kr 16M
3Y CAGR: -15.7%
Continue Research
Pila Pharma AB (PILA.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Pila Pharma AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Pila Pharma AB scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -713.0% operating margin and a -63.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh PILA.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.